Apostle
Pleasanton
About Apostle
Apostle Inc is a biotechnology company in San Jose, CA, a provider of innovative technologies and services for public health and life sciences. Apostle aims to develop innovative technologies in the space of liquid biopsy - the sampling and analysis of non-solid biological tissue, primarily blood, often utilizing circulating free DNA (cfDNA) as a biomarker. Apostle’s innovations include Apostle MiniMax, a new scalable and automatable method to efficiently capture cfDNA from a standard blood draw; Apostle MagTouch, a nucleic acids isolation automation system, and Apostle MiniEnrich, a high-resolution DNA size enrichment technology using a magnetic nano-platform. Since 2020, the company has responded to the COVID-19 pandemic to help our community fight together with a high quality, low cost, fast, automated, Apostle COVID-19 Viral RNA Isolation System. Up to date, Apostle’s technology has served over 13 million people. Apostle Diagnostics a CLIA Certified, California State Licensed, CAP Accredited Clinical Laboratory, and is a clinical laboratory branch of Apostle Inc. The laboratory is co-directed by Wenqi Zeng, MD, PhD, FACMG and Charles Strom, MD, PhD, FAAP, FACMG, HCLD. The laboratory upholds the people-oriented and science-oriented service concept and is committed to serving the community and providing accurate, strict and timely clinical testing services. To date, Apostle Diagnostics has served more than 30,000 people.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $5.7M
- Funding stage: Early Stage Venture
- Last round: Series A (May 2019)
- Website: apostlebio.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Health Care, Health Diagnostics, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/apostle-62384 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.